These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

933 related articles for article (PubMed ID: 16689923)

  • 1. Protein-misfolding diseases and chaperone-based therapeutic approaches.
    Chaudhuri TK; Paul S
    FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein misfolding in neurodegenerative diseases.
    Agorogiannis EI; Agorogiannis GI; Papadimitriou A; Hadjigeorgiou GM
    Neuropathol Appl Neurobiol; 2004 Jun; 30(3):215-24. PubMed ID: 15175075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of neurodegeneration by molecular chaperones.
    Muchowski PJ; Wacker JL
    Nat Rev Neurosci; 2005 Jan; 6(1):11-22. PubMed ID: 15611723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the mysteries of protein folding and misfolding.
    Ecroyd H; Carver JA
    IUBMB Life; 2008 Dec; 60(12):769-74. PubMed ID: 18767168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How a cell deals with abnormal proteins. Pathogenetic mechanisms in protein aggregation diseases.
    Aigelsreiter A; Janig E; Stumptner C; Fuchsbichler A; Zatloukal K; Denk H
    Pathobiology; 2007; 74(3):145-58. PubMed ID: 17643060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of disease II: cellular protein quality control.
    Outeiro TF; Tetzlaff J
    Semin Pediatr Neurol; 2007 Mar; 14(1):15-25. PubMed ID: 17331880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteopathy: the next therapeutic frontier?
    Walker LC; LeVine H
    Curr Opin Investig Drugs; 2002 May; 3(5):782-7. PubMed ID: 12090553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of molecular chaperones in human misfolding diseases.
    Broadley SA; Hartl FU
    FEBS Lett; 2009 Aug; 583(16):2647-53. PubMed ID: 19393652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing therapeutics for the diseases of protein misfolding.
    May BC; Govaerts C; Cohen FE
    Neurology; 2006 Jan; 66(2 Suppl 1):S118-22. PubMed ID: 16432139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic approaches to protein-misfolding diseases.
    Cohen FE; Kelly JW
    Nature; 2003 Dec; 426(6968):905-9. PubMed ID: 14685252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neurodegenerative conformational disease and its molecular bases].
    Li WW; Cai DF; Ren HM
    Sheng Li Ke Xue Jin Zhan; 2006 Apr; 37(2):97-102. PubMed ID: 16850610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and function of the molecular chaperone Hsp104 from yeast.
    Grimminger-Marquardt V; Lashuel HA
    Biopolymers; 2010 Mar; 93(3):252-76. PubMed ID: 19768774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches to the isolation and characterization of molecular chaperones.
    Nicoll WS; Boshoff A; Ludewig MH; Hennessy F; Jung M; Blatch GL
    Protein Expr Purif; 2006 Mar; 46(1):1-15. PubMed ID: 16199180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease.
    Glabe CG
    Neurobiol Aging; 2006 Apr; 27(4):570-5. PubMed ID: 16481071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small heat-shock proteins and clusterin: intra- and extracellular molecular chaperones with a common mechanism of action and function?
    Carver JA; Rekas A; Thorn DC; Wilson MR
    IUBMB Life; 2003 Dec; 55(12):661-8. PubMed ID: 14769002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective protein folding and aggregation as the basis of neurodegenerative diseases: the darker aspect of proteins.
    Naeem A; Fazili NA
    Cell Biochem Biophys; 2011 Nov; 61(2):237-50. PubMed ID: 21573992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino acid sequence determinants and molecular chaperones in amyloid fibril formation.
    Nerelius C; Fitzen M; Johansson J
    Biochem Biophys Res Commun; 2010 May; 396(1):2-6. PubMed ID: 20494101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling and analysis of prion dynamics in the presence of a chaperone.
    Kumar R; Murali P
    Math Biosci; 2008 May; 213(1):50-5. PubMed ID: 18362035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of glutamatergic signaling to nitrosative stress-induced protein misfolding in normal brain aging and neurodegenerative diseases.
    Nakamura T; Gu Z; Lipton SA
    Aging Cell; 2007 Jun; 6(3):351-9. PubMed ID: 17388798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S-Nitrosylation and uncompetitive/fast off-rate (UFO) drug therapy in neurodegenerative disorders of protein misfolding.
    Nakamura T; Lipton SA
    Cell Death Differ; 2007 Jul; 14(7):1305-14. PubMed ID: 17431424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.